Company record

Biolevate

Updated October 19, 2026 · Presspool

Biolevate is the evidence-grade AI platform that automates scientific and regulatory workflows for life sciences teams. biolevate.com

Funding

• €30 million Series A, announced September 22, 2026. Led by RAISE France and Orange Ventures. MSD Global Health Innovation Fund participated; Biolevate is opening a Boston office. Listed in the AI startup funding roster for September 21–26, 2026. Sources: Biolevate, Tech.eu.

Of the 6 Series A rounds with exactly stated amounts in euros on Presspool's weekly rosters since September 21, 2026, Biolevate's €30 million is the largest; their median is €11 million.

Whether AI names Biolevate

• Machine Relations Index: Not cited in any Machine Relations Index answer, May 10, 2026 to October 18, 2026.

A company counts when an AI answer names it or cites its website. Answers vary from run to run, so each count is a dated sample.

Related records

Closest rounds in the roster for September 21–26, 2026: Axya (CA$17 million Series A, September 24, 2026), Basalt Health ($20 million Series A, September 24, 2026), PicoJool ($27.5 million Series A, September 24, 2026), Baselayer ($35 million Series A, September 22, 2026), Chamelio ($26 million Series A, September 22, 2026), Go.AI ($85 million Series A, September 22, 2026).

Sources

• Biolevate
• Tech.eu

Every fact on this page links its source. Corrections need a public source: see Contact.